MarketPulse

anti-obesity market

2 articles
The Motley FoolThe Motley Fool··David Jagielski, Cpa

Intuitive Surgical's da Vinci Systems: The Surgical Edge in Booming Weight-Loss Market

Intuitive Surgical's da Vinci surgical systems offer superior long-term weight-loss outcomes versus GLP-1 drugs. Strong 28% margins and double-digit revenue growth position $ISRG as overlooked obesity-market beneficiary despite 20% year-to-date decline.
ISRGGLP-1 drugsweight loss
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Oral GLP-1 Drug Could Reshape Weight Loss Market as Novo Nordisk Faces Competition

Eli Lilly's orforglipron oral GLP-1 drug offers no food restrictions and dual obesity-diabetes approval potential, threatening Novo Nordisk's oral Wegovy dominance.
LLYNVOpharmaceutical competitionweight-loss drug